NTV Asset Management LLC Sells 748 Shares of Novo Nordisk A/S $NVO

NTV Asset Management LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 7.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,206 shares of the company’s stock after selling 748 shares during the quarter. NTV Asset Management LLC’s holdings in Novo Nordisk A/S were worth $635,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Revolve Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares in the last quarter. Rhumbline Advisers increased its stake in Novo Nordisk A/S by 10.2% in the 1st quarter. Rhumbline Advisers now owns 63,539 shares of the company’s stock worth $4,412,000 after buying an additional 5,898 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in Novo Nordisk A/S by 1.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 20,032 shares of the company’s stock worth $1,391,000 after buying an additional 290 shares in the last quarter. Beacon Financial Group increased its stake in Novo Nordisk A/S by 6.5% in the 1st quarter. Beacon Financial Group now owns 2,884 shares of the company’s stock worth $200,000 after buying an additional 177 shares in the last quarter. Finally, Naples Global Advisors LLC purchased a new stake in Novo Nordisk A/S in the 1st quarter worth $829,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. Barclays reiterated an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Morgan Stanley lowered Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and cut their price target for the stock from $59.00 to $47.00 in a research note on Monday. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $77.50.

Novo Nordisk A/S Trading Up 1.6%

Shares of Novo Nordisk A/S stock opened at $59.68 on Friday. The firm has a market cap of $266.45 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 2.25 and a beta of 0.68. The business has a 50-day moving average price of $54.92 and a 200-day moving average price of $63.84. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.